Updated
Updated · ScienceDaily · Jul 11
DT-109 Reverses Severe MASH in Animals by Repairing Gut Barrier, Targeting Disease Affecting 7%
Updated
Updated · ScienceDaily · Jul 11

DT-109 Reverses Severe MASH in Animals by Repairing Gut Barrier, Targeting Disease Affecting 7%

3 articles · Updated · ScienceDaily · Jul 11

Summary

  • Animal studies showed DT-109 reversed severe MASH by restoring the intestinal barrier and cutting the flow of harmful microbial products to the liver.
  • Researchers traced the effect to lower Clostridium perfringens levels and reduced gut ammonia, which otherwise damages the gut lining and triggers liver inflammation, including excess CD8+ T-cell activity.
  • Mice and nonhuman primates both improved, with the primate results standing out because their liver biology and gut microbiota more closely resemble humans.
  • About 7% of people worldwide have MASH, a fatty liver disease that can progress to cirrhosis, liver cancer and liver failure, while effective treatments remain limited.
  • The University of Michigan team said more testing is needed before clinical trials; DT-109 is patented and licensed to Diapin Therapeutics, which is continuing development.

Insights

A new liver drug repairs the gut. Could it also treat heart disease and digestive disorders?
As weight-loss drugs enter the MASH market, can this new gut-focused pill offer a more direct cure?

DT-109 Shows Preclinical Success in Reversing MASH by Targeting Gut Microbiome: Human Trials on the Horizon

Overview

Metabolic Dysfunction-Associated Steatohepatitis (MASH) is a major health challenge, and as of July 2026, effective treatments are still needed. Recent preclinical research highlights DT-109, an experimental drug that shows strong potential in reversing MASH in animal models. DT-109 works by protecting the gut epithelial barrier, which helps reduce the entry of harmful microbial products into the body—factors known to drive MASH progression. This gut-focused approach not only benefits the gastrointestinal system but also represents a promising step forward in the search for therapies that can truly reverse MASH.

...